Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Kinnevik (OM:KINV B) has drawn fresh attention after investing €20m in hospitality software provider Mews and US$100m in digital health company Oviva, and has taken leading shareholder positions in both AI-focused platforms.
See our latest analysis for Kinnevik.
These new positions in Mews and Oviva come as Kinnevik’s share price sits at SEK76.18, with a 7 day share price return of 9.37% decline and a year to date share price return of 7.12% decline. The 5 year total shareholder return of 63.08% decline points to longer term pressure and suggests recent interest around its AI and digital health exposure is yet to translate into a sustained recovery.
If Kinnevik’s push into AI driven platforms has caught your eye, it could be worth broadening your search across high growth tech and AI stocks for more potential ideas in the space.
With Kinnevik’s shares down over 60% on a 5 year view and recent AI and digital health deals back in focus, investors may be asking whether this represents a reset entry point or whether the market is already pricing in future growth.
At a last close of SEK76.18 versus a most-followed fair value of about SEK101.33, Kinnevik is framed as materially mispriced by this narrative.
Accelerating adoption of AI powered software across hospitality, travel, health care and fintech is driving step changes in automation, personalization and decision quality in portfolio companies like Mews, TravelPerk and Spring Health, which should support sustained high revenue growth and structurally higher gross margins over time.
Read the complete narrative.
Curious how this AI push translates into the SEK101 valuation anchor? Revenue expansion, margin shifts and future earnings power all sit at the core of this story. The projections are bold, but tightly modelled around a very specific earnings profile and end point multiples. Want to see which assumptions really move the fair value needle here?
Result: Fair Value of SEK101.33 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, those bold earnings assumptions rely on healthier software valuations, as well as smooth execution at key AI and digital health holdings, with currency swings also capable of distorting reported progress.
Find out about the key risks to this Kinnevik narrative.
If you see the story differently or prefer to weigh the numbers yourself, you can build a custom Kinnevik view in just a few minutes, starting with Do it your way.
